Search clinical trials for: BR and Ibrutinib

Total 269965 results

Pepperdine University

Recruiting

The Effect of Beetroot Juice Supplementation Dose on Neuromuscular Performance During Resistance Exercise

High Nitrate Dose | Moderate Nitrate Dose | Low Nitrate Dose | Nitrate-depleted Dose

United States
University of Thessaly

Completed

Metabolic Cost of Battle Rope Training (BRT-UTH)

Body Composition | Physical Fitness | Energy Expenditure | Resting Metabolic Rate

Greece
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (BDHCLL001)

Chronic Lymphocytic Leukemia

China
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers

Healthy
Boryung Pharmaceutical Co., Ltd
Covance

Completed

Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects

Essential Hypertension
Boryung Pharmaceutical Co., Ltd

Completed

Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K) (Fimasartan)

Essential Hypertension
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
Boryung Pharmaceutical Co., Ltd

Completed

Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion (STIFFNESS)

Hypertension

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults

Healthy

Belgium
Oncternal Therapeutics, Inc
University of California, San Diego; Pharmacyclics LLC.; California Institute...

Active, not recruiting

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
TG Therapeutics, Inc.

Completed

Ublituximab + Ibrutinib in Select B-cell Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia

United States
Boehringer Ingelheim

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers

Healthy
Johnson & Johnson Private Limited

Completed

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

India
Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Healthy

United States
Boryung Biopharma Co., Ltd.

Completed

To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

Tetanus | Diphtheria

Korea, Republic of
Hospital do Coracao

Completed

Brazilian Cardioprotective Nutritional Program Trial (BALANCE)

Cardiovascular Diseases

Brazil
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

Healthy
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson

Enrolling by invitation

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host Disease

United States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
Janssen-Cilag Ltd.

Completed

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (FIRE)

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

France
The Lymphoma Academic Research Organisation

Completed

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

Intraocular Lymphoma | Primary Central Nervous Lymphoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

Chronic Lymphocytic Leukemia

Italy
Memorial Sloan Kettering Cancer Center

Completed

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Lymphoma | Mantle Cell Lymphoma

United States
Janssen-Cilag S.p.A.

Completed

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting (EVIdeNCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Italy
The First Affiliated Hospital with Nanjing Medical...
Xian-Janssen Pharmaceutical Ltd.

Unknown

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Kimberly-Clark Corporation

Completed

Tampon Design Validation Study

Menstruation

United States
Medical University of Warsaw

Unknown

Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients

Kidney Transplantation | Arterial Calcification | Aortic Stiffness | High Blood Pressure

Poland
Peking University People's Hospital
Beijing Hospital

Unknown

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Leukemia, Lymphocytic, Chronic, B-Cell
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Mantle Cell Lymphoma (MCL)

United States, Poland, Italy
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease

Chronic Graft-versus-host-disease

Mexico
Federal University of Health Science of Porto Alegre

Completed

Effects of Muscle Trainins Inspiratory Linked to Cardiac Rehabilitation Post-operative of CABG Surgery

Cardiovascular Diseases

Brazil
IRCCS San Raffaele

Recruiting

Real World Data on Ibrutinib Use in PCNSL Rel/Ref (ReWIPretro)

PCNSL

Italy
Memorial Sloan Kettering Cancer Center
Ohio State University; Pharmacyclics LLC.; Janssen Biotech, Inc.

Completed

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

T-cell Lymphoma | Relapsed and Refractory T-cell Lymphoma

United States
University of Cologne

Completed

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) (IRENO)

Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Germany
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; Pharmacyclics LLC.

Terminated

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Follicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIa

United States
Janssen Biotech, Inc.
Pharmacyclics LLC.

Approved for marketing

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

United States, Brazil, Puerto Rico
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals

Completed

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
University of Michigan Rogel Cancer Center

Withdrawn

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Healthy

United States
US Oncology Research
AbbVie; Pharmacyclics LLC.

Active, not recruiting

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Breast Neoplasms | Malignant Neoplasm of Breast

United States
Pirogov Russian National Research Medical University

Unknown

Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Russian Federation
The University of Hong Kong
Janssen, LP

Unknown

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Follicular Lymphoma | Chronic Hepatitis B | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Indolent B-cell Lymphomas | Waldenstrom's Macroglobulinaemia

Hong Kong
Janssen Research & Development, LLC

Withdrawn

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell
Sanofi

Completed

Dermacyd Breeze Pocket BR (Lactic Acid) - Acceptability

Hygiene

Brazil
Jeanette Lundin

Recruiting

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) (IbruOnOff)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Sweden, Norway
Novartis Pharmaceuticals

Terminated

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Diffuse Large B-cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

United States

Search clinical trials for: BR and Ibrutinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations